Here are the 10-K annual reports from Rockwell Medical, Inc. (DE) (RMTI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow RMTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RMTI filings page.
Rockwell Medical details its hemodialysis concentrates business, 2025 milestones, and mounting risks in its annual report. The company serves 294 customers, including all five leading U.S. dialysis providers, with dialysate concentrates making up 100% of 2025 revenue and about 88% of sales in the United States.
DaVita accounted for 16% of 2025 net product sales, down from 45% in 2024, after an attempted transition to another supplier. A second amendment extended Rockwell’s DaVita supply agreement through December 31, 2026 with higher pricing. Rockwell ended manufacturing at its South Carolina facility to streamline costs and added 30 new western U.S. customers.
At December 31, 2025, Rockwell reported about $25.0 million in cash, cash equivalents and available-for-sale investments, working capital of $28.6 million, and net cash used in operations of roughly $0.7 million for the year. Management believes capital is sufficient for at least 12 months but warns that additional funding, covenant compliance under its Innovatus term loan, customer concentration, cost inflation, and evolving kidney disease treatments could materially affect future results.